NCT06660329View on ClinicalTrials.gov

Efficacy and Safety of Tofacitinib in Refractory Blau Syndrome

PHASE4Enrolling by invitationINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

October 1, 2024

Primary Completion Date

October 1, 2027

Study Completion Date

October 1, 2028

Conditions
Blau Syndrome
Interventions
DRUG

Janus Kinase Inhibitor

Tofacitinib is used according to weight: 5\~\<7kg，2mg；7\~\<10kg，2.5mg；10\~\<15kg，3mg；15\~\<25kg，3.5mg；25\~\<40kg，4mg；≥40kg，5mg. All is twice a day.

Trial Locations (1)

100730

Peking Union Medical College Hospital, Beijing

All Listed Sponsors
lead

Peking Union Medical College Hospital

OTHER